Table 2 Characteristics of acute PE patients with intermediate early mortality risk who died and survivors at 1-year follow-up.
Variable | PE-related death (n = 9) | Survivors (n = 97) | P value |
|---|---|---|---|
Age, years | 68 [61–80] | 58 [40–70] | 0.032 |
Men, n (%) | 4 (44.4) | 49 (50.5) | 0.73 |
Body-mass index, kg/m2 | 26 [23–30] | 27 [24–31] | 0.28 |
Characteristics of acute PE | |||
Intermediate-low mortality risk, n (%) | 2 (22.2) | 75 (89.3) | 0.0004 |
Intermediate-high mortality risk, n (%) | 7 (77.8) | 22 (26.2) | |
Right ventricular dysfunction, n (%) | 8 (88.9) | 38 (39.2) | 0.004 |
Unprovoked PE, n (%) | 7 (77.8) | 64 (66) | 0.47 |
Clinical characteristics, n (%) | |||
Prior venous thromboembolism, n (%) | 0 | 6 (6.2) | 0.58 |
Coronary heart disease, n (%) | 3 (33.3) | 40 (41.2) | 0.64 |
Prior myocardial infarction, n (%) | 2 (22.2) | 22 (22.7) | 0.97 |
Prior stroke, n (%) | 1 (11.1) | 8 (8.2) | 0.77 |
Hypertension, n (%) | 3 (33.3) | 56 (57.7) | 0.16 |
Heart failure, n (%) | 2 (22.2) | 23 (23.7) | 0.92 |
Diabetes mellitus, n (%) | 3 (33.3) | 33 (34) | 0.97 |
Chronic obstructive pulmonary disease, n (%) | 0 | 12 (12.4) | 0.59 |
Laboratory investigations | |||
Endogenous thrombin potential, nM × min | 2088 [1765–2593] | 1688 [1499–1943] | 0.031 |
Citrullinated histone H3, ng/mL | 4.49 [3.66–5.62] | 3.1 [1.9–3.98] | 0.038 |
Ks, × 10-9cm2 | 5.60 [4.90–5.91] | 6.35 [5.45–7.2] | 0.066 |
CLT, min | 129 [115–149] | 109 [99–124] | 0.029 |
